Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Biosimilars Great Debate: To Switch or Not?

  |  

The U.S. is in a rebate trap that keeps drug prices high across the system, Dr. Kay said.6 Payers who give biosimilars a preferred tier position on their formularies may then lose rebates from reference product makers, “so it’s only if virtually all of the patients go to the biosimilar does the rebate rap not affect the payer,” he said.

Payers in the U.S. give preferred positions only to the drugs that drive up their profits, not those that boost savings for patients, said Dr. Fleischmann.

ADVERTISEMENT
SCROLL TO CONTINUE

“This is the reality of the situation. You can tell me what should be, but that isn’t happening right now. I’m not saying it’s correct, but it’s the reality,” Dr. Fleischmann said.

Susan Bernstein is a freelance journalist based in Atlanta.

ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol Dial Transplant. 2008 Oct 2006;21(suppl 5):v4–v8.
  2. Schiestl M, Stangler T, Torella C, et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011 Apr;29(4):310–312.
  3. Jorgensen KK, Olsen IC, Lorentzen M, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): A 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017 Jun;389(10086):2304–2316.
  4. Glintborg B, Sorensen IJ, Loft AG, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017 Aug;76(8):1426–1431.
  5. Kay J, Schoels MM, Dorner T, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2017 Sep. Epub ahead of print.
  6. Hakim A, Ross JS. Obstacles to the adoption of biosimilars for chronic diseases. JAMA. 2017 Jun 6;317(21):2163–2164.

Related Articles

    Should Patients with Rheumatic Disease Switch from Biologic to Biosimilar?

    SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked…

    Medicalwriters/Science Source

    Biosimilars Are Slowly Climbing Toward Acceptance in Rheumatology

    As useful stand-ins for biologics targeting a range of inflammatory diseases, biosimilars have made significant inroads across Europe as less expensive alternatives. Denmark, for example, realized a cost savings of 64% after instituting a mandatory national switch from the originator infliximab to its biosimilar counterpart. In the U.S., however, a considerably smaller fraction of rheumatologists…

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…